drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (allogeneic CAR NK cells)
drug_description
Allogeneic, cord blood–derived CAR natural killer (NK) cell therapy engineered to express two CARs targeting CD19 and CD70; administered IV to induce MHC-independent NK cytotoxicity against B-cell malignancies and reduce antigen escape.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Receptors, Chimeric Antigen
drug_category
CAR NK
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Allogeneic cord blood-derived NK cells engineered to express two chimeric antigen receptors targeting CD19 and CD70. Binding to either antigen activates NK cell signaling and MHC-independent cytotoxicity (perforin/granzyme-mediated lysis and cytokine release) against malignant B cells, with dual targeting designed to reduce antigen escape.
drug_name
dualCAR-NK19/70
nct_id_drug_ref
NCT05842707